Skip to main content

Table 1 Clinical and demographical characteristics of PsA patients and controls

From: MiR-146a G/C rs2910164 variation in South African Indian and Caucasian patients with psoriatic arthritis

  PsA patients
(n = 117)
Controls
(n = 100)
p value
Age (years) 50.34 ± 1.14 46.23 ± 1.56 0.0309*
Sex
 Male, n (%) 63 (54) 35 (35)  
 Female, n (%) 54 (46) 65 (65)  
Race
 Indian, n (%) 84 (72) 62 (62)  
 White, n (%) 32 (27) 38 (38)  
 Mixed Race, n (%)b 1 (1) 0 (0)  
BMI (kg/m2) 28.86 ± 0.50 27.85 ± 0.42 0.1307
Smoker
 Yes, n (%) 25 (21)  
 No, n (%) 92 (79)
Disease duration (years) 6.43 ± 0.67
Radiology  
 Yes, n (%) 84 (72)
 No, n (%) 33 (28)
HAQ score 0.62 ± 0.07
RF-IgM  
 Positive, n (%) 5 (4)
 Negative, n (%) 112 (96)
Drugs
 MTX, n (%) 111 (95)  
 SSZ, n (%) 33 (28)
 LFM, n (%) 21 (18)
 Biologics, n (%)a 9 (8)
CRP (mg/L)
 Inclusion 18.95 ± 2.81   0.0011*
 @ 6 month 9.68 ± 1.32   
Plasma glucose (mmol/l) 6.17 ± 0.21  
Total cholesterol (mmol/l) 5.11 ± 0.10
LDL cholesterol (mmol/l) 3.26 ± 0.12
HDL cholesterol (mmol/l) 1.14 ± 0.03
HbA1c (%) 5.85 ± 0.13
Vitamin D25 (ng/ml) 20.31 ± 1.34
  1. Laboratory parameters are represented as mean ± standard error. Comparisons for age, BMI and CRP levels were performed using the unpaired Student’s t-test
  2. PsA psoriatic arthritis, BMI body mass index, HAQ health assessment questionnaire, RF-IgM rheumatoid factor-immunoglobulin M, MTX methotrexate, SSZ sulfasalazine, LFM leflunomide, CRP C-reactive protein, LDL low density lipoprotein, HDL high density lipoprotein, HbA1c: blood glycated haemoglobin
  3. *A p < 0.05 was considered as being significant
  4. aBiologics: etanercept, adalimumab and infliximab. bMixed Race: Caucasian and Indian descent